


Tijeras-Raballand et al. Supplementary Figure 1



Supplementary Fig. 1


A, Representative images of Desmin (green)/CD31(red) double immunostaining in normal livers (n=4), untreated HCC and rosuvastatin-treated HCC livers (n=4/group). CD31-stained endothelial cells in VDPT (white arrow) and sinusoids (white arrowhead). Desmin-stained mural cells in vessels derived from the portal tract (empty arrow) and non-activated HSCs surrounding the sinusoid vessels (empty arrowhead). CD31-positive

sinusoidal endothelial cells were more surrounded by desmin-positive HSCs under rosuvastatin treatment in HCC livers.

B, Representative images of SMA (red)/CD31(green) double-immunostaining, in normal livers (n=4), untreated HCC and rosuvastatin-treated HCC livers (n=4/group). CD31-stained endothelial cells in VDPT (white arrow) and sinusoids (white arrowhead). SMA-stained smooth muscle cells in arteries (empty arrow) and activated HSCs (empty arrowhead) surrounding the sinusoids. CD31-positive sinusoidal endothelial cells were less surrounded by SMA-positive activated HSCs under rosuvastatin treatment in HCC livers.

Tijeras-Raballand et al. Supplementary Figure 2

Negative controls



Supplementary Fig. 2

Representative images of negative controls. The primary antibody was omitted, or incubated with an excess of blocking peptide as a negative control.